<DOC>
	<DOCNO>NCT00460057</DOCNO>
	<brief_summary>High bone turnover bone resorption exceed bone formation major mechanism postmenopausal osteoporosis . Therefore , inhibition bone resorption rational approach prevention . The Objective current study determine short-term efficacy once-weekly low dose alendronate prevention bone loss early postmenopausal Korean woman moderate bone loss via bone turnover marker . This study 12-week , randomize , double-blind clinical trial compare effect placebo alendronate 20 mg weekly . All subject receive supplemental calcium 600 mg vitamin D 400 IU daily . Fifty two postmenopausal woman ( age 50-65 year ) lumbar spine BMD least 2.0 SD peak young adult mean recruit Eulji University Hospital , Daejeon , Korea . BMD measure DXA baseline serum alkaline phosphatase , osteocalcin C-terminal telopeptide type I collagen measure baseline 12 week treatment .</brief_summary>
	<brief_title>The Change Bone Markers After Low Dose Alendronate Postmenopausal Women With Bone Loss</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>postmenopausal woman ( age 5065 year ) lumbar spine BMD least 2.0 SD peak young adult mean severe osteoporosis current medication osteoposis metabolic bone disease cancer , stroke etc .</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>alendronate</keyword>
	<keyword>bone marker</keyword>
</DOC>